PROCEPT BioRobotics Corporation
NASDAQ:PRCTMedical - Devices
+$0.19 today
- Market cap
- $1.45B
- Beta
- 0.85
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.81
Volume 2.05M
Average 1.46M
PRCT Interest Expense
Cost of servicing the company's debt during the period.
PROCEPT BioRobotics CorporationNASDAQ: PRCT
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense declines year over year
Q1 FY2026 interest expense of $818K fell 6.7% year over year, ahead of the -12.2% change in trailing-twelve-month interest expense. Sequentially, it fell 8.5% from the prior quarter. Over 3 fiscal years it compounded at -11.6% a year.
Context
- Interest expense amounted to 1.2% of revenue in FY2025, down 0.7 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -6.7% holds above the trailing-twelve-month pace of -12.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 3.59M USD
- Year-over-year change
- -14.3%
- 4-year CAGR
- -11.4%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.59M | -14.3% |
| FY2024 | 2024-12-31 | 4.18M | +4.7% |
| FY2023 | 2023-12-31 | 4M | -22.9% |
| FY2022 | 2022-12-31 | 5.18M | -10.8% |
| FY2021 | 2021-12-31 | 5.81M | — |
Interest Expense vs competitors
How PRCT compares with its peers on the latest reported figures
- PRCT's LTM Mar 2026 interest expense of $3.53M is the 2nd highest of the 5 companies compared; the peer median is $1.86M.
- Its year-over-year change of -12.2% is the lowest of 2, against a peer median of +8.0%.
- Interest expense amounts to 1.1% of revenue for PRCT, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
FOCLEDAP TMS S.A. American Depositary Shares | LTM Mar 2026 | $4.85M | — | +64.9% | 6.5% |
| LTM Mar 2026 | $3.53M | -12.2% | -11.6% | 1.1% | |
| LTM Mar 2026 | $2.71M | — | +208.9% | 6.7% | |
| LTM Mar 2026 | $1.01M | +8.0% | +89.9% | 2.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PRCT) | $1.86M | +8.0% | +89.9% | 4.3% | |
Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.47M | 75.01M | 136.19M | 224.5M | 308.05M |
| Cost of Revenue | 18.61M | 37.93M | 65.14M | 87.4M | 111.83M |
| Gross Profit | 15.87M | 37.09M | 71.05M | 137.1M | 196.23M |
| Gross Margin | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Research & Development | 18.99M | 28.98M | 48.45M | 62.3M | 71.28M |
| Selling, General & Admin | 51.04M | 88.83M | 131.77M | 171.42M | 228.81M |
| Operating Expenses | 70.03M | 117.81M | 180.22M | 233.71M | 300.09M |
| Depreciation & Amortization | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M |
| EBITDA | (50.72M) | (79.13M) | (98.1M) | (82M) | (85.41M) |
| EBITDA Margin | -147.1% | -105.5% | -72.0% | -36.5% | -27.7% |
| Operating Income | (54.16M) | (80.72M) | (109.17M) | (96.61M) | (103.86M) |
| Operating Margin | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% |
| Interest Income | 76K | 2.5M | 7.55M | 10.9M | 12.22M |
| Interest Expense | 5.81M | 5.18M | 4M | 4.18M | 3.59M |
| Other Income / Expenses | (5.69M) | (6.43M) | 3.27M | 5.2M | 8.48M |
| Income Before Tax | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.38M) |
| Pre-Tax Margin | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 190K |
| Net Income | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.57M) |
| Net Margin | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| EPS (Basic) | (1.37) | (1.96) | (2.24) | (1.75) | (1.72) |
| EPS (Diluted) | (1.37) | (1.96) | (2.24) | (1.75) | (1.72) |
| Weighted Avg Shares | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M |
| Weighted Avg Shares (Diluted) | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M |
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
Intrinsic Alpha fair value
Locked
Current Price
$25.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.